Advanced Filters
noise

Human Papilloma Virus (HPV) Clinical Trials

A listing of Human Papilloma Virus (HPV) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 196 clinical trials
C Christina Bliss Barsness

HPV Self-Sampling in Somali Women

This study plans to assess the effect of implementing HPV self-sampling in primary care on uptake of cervical cancer screening in 30-65 year old Somali women who are due for cervical cancer screening.

30 - 65 years of age Female Phase N/A

Self-sampling for Non-attenders to Cervical Cancer Screening

The trial will evaluate whether self-sampling and human papillomavirus (HPV) testing may increase cervical cancer screening attendance among under-screened women in Czech Republic. Different ways of offering self-sampling device will be evaluated.

30 - 65 years of age Female Phase N/A
M Malin Vikström, BSN

Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden

The study aims to evaluate whether organised, concomitant HPV vaccination and HPV screening offered to all resident women aged 22-27 will result in a more rapid elimination of HPV infection in Sweden. This objective will be examined at the population level.

22 - 27 years of age Female Phase 4
S Sónia Dias

ELEVATE Acceptability Study

This study includes a community-based, two-arm prospective acceptability study, whereby arm 1 consists of an educational session on sexual health and cervical cancer (screening) and a follow-up assessment after 3 months. Arm 2 consists of an educational session on sexual health and cervical cancer (screening) and self-sampling, additionally women will …

25 - 65 years of age Female Phase N/A

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

An open-label, controlled, multi-site, interventional, 2-arm, Phase II trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death ligand -1 (PD-L1) with combined positive score (CPS) ≥1. This trial has two parts. Part …

18 - 100 years of age Both Phase 2
A Adamu Meghersa

Cervical Cancer Screening by Self-sampling in a Cohort of Younger Women in Ethiopia

The overall purpose of the project is to evaluate an algorithm for an HPV self-sampling based cervical cancer screening algorithm in a mid-size town in Ethiopia that could be applicable for nationwide implementation in low and middle-income countries (LMIC). Specific aims are the following: To evaluate the algorithm using Visual …

18 - 100 years of age Female Phase N/A
H Huakun Lv

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years

9 - 45 years of age Female Phase 3
S Severien Van Keer, MSc, PhD

Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial

The goal of the ScreenUrSelf trial is to increase cervical cancer screening attendance and compliance to follow-up by offering a first-void urine self-sampling alternative to women who are currently not participating in the organized cervical cancer screening program (defined in this project as un(der)-screened women), either on the woman or …

31 - 64 years of age Female Phase N/A
J Joakim Dillner, MD, PhD

HPV-based Screening Among Women 23-29 Years of Age

The aim of the trial is to determine whether organized screening with primary HPV analysis provide higher cancer protection in the age group 23-29 years compared to primary cytology.

23 - 29 years of age Female Phase N/A
Q Quanyou Liu

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years

9 - 26 years of age Female Phase 3

Rewrite in simple language using AI